Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Suit vs. Forest Labs Names Execs Linked to Alleged Lies About Lexapro, Celexa
- Employees of Forest Labs and that company's rivals should read the U.S. government's complaint against the company, which alleges off-label promotion of Lexapro and Celexa for use in children. The complaint names executives, indicates who knew what and when, and goes into the details of many individual sales reps' actions....
- Blog posts 2009-02-26
Additional Resources
- IVAX Responds to Article on Australian Pharmaceutical Company's CELEXA Patent Challenge
- MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) announced today that contrary to a report issued by World Markets Research Centre on a recent court decision regarding Alphapharm Pty Limited v. Tommy G. Thompson, Secretary of Health and Human Services, in Civil Action No. 03-2269 and the drug product CELEXAR, the Memorandum...
- Research articles 2004-08-19
- Aberdeen Celexa leads the way in a quiet revolution.
- When Aberdeen Property Investors bought Celexa in April, it was the first acknowledgement of a quiet revolution in the world of European property fund management. When Aberdeen Property Investors bought Celexa in April, it was the first acknowledgement of a quiet revolution in the...
- Research articles 2001-09-17
- Forest Labs surprises with strong Celexa sales. (Life Sciences).(Brief Article)(Statistical Data Included)
- FOREST LABORATORIES Inc. surprised on the upside for fiscal second quarter 2003 earnings last week, sent shares of the specialty pharmaceuticals company up $7.84, to $89.85. Forest Labs projects earnings per share EPS to be above the consensus estimate of 57 cents per share by at...
- Research articles 2002-10-07
- Forest Labs Q1: $170 Million Fee for DOJ; Its Numbers Are Written in "Invisible Ink"
- Forest Labs is holding a $170 million contingency fee in case it needs to settle allegations by the Department of Justice that it bribed doctors --- with such things as $1,000 gift certificates to Alain Ducasse -- into prescribing Lexapro and Celexa for children even though it was not approved...
- Blog posts 2009-04-23
- Drug revenues give shot in the arm; Antidepressant boosts Forest Labs; analysts want more winners.
- Analysts say they have one word to explain the steady climb in the share price of Forest Laboratories Inc.: Celexa. When the Manhattan-based company first started selling the antidepressant drug in September 1998, its stock was trading at around $40. Analysts say they have one word...
- Research articles 2000-05-29
- IVAX Receives Final Approval on Citalopram Hydrobromide Tablets
- MIAMI -- IVAX Corporation (AMEX:IVX) (LSE:IVX.L) received final approval from the Federal Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for citalopram hydrobromide tablets in 10, 20, and 40 mg dosages. Citalopram is the generic equivalent of CelexaR, which is marketed by Forest Pharmaceuticals for the...
- Research articles 2004-11-17
- Alecta Sells Celexa to Aberdeen Asset Management
- Business Editors
- Research articles 2001-04-17
- Biovail Completes Development of New Celexa Formulation; Lundbeck to Initiate Phase III Studies
- Business Editors, Health/Medical Writers
- Research articles 2000-06-29
- Forest Laboratories Inc. (Active Pharmaceutical Ingredient Watch).(fiscal 2003 third quarter results)(Brief Article)
- FOREST Laboratories Inc. preannounced its fiscal 2003 third quarter results. The company projects that earnings per share EPS will ... FOREST Laboratories Inc. preannounced its fiscal 2003 third quarter results. The company projects that earnings per share EPS will exceed the current consensus estimate...
- Research articles 2003-01-13
- Eon Labs Receives Final Approval for Citalopram HBr Tablets and Will Begin Shipping Immediately
- LAURELTON, N.Y. -- Eon Labs, Inc. (Nasdaq: ELAB) announced today that it received final approval for Citalopram HBr, the generic equivalent of CelexaRa tablets, in the same strengths as the brand, 10mg, 20mg and 40mg. The introduction of Citalopram HBr represents another first to market product for Eon Labs. The...
- Research articles 2004-10-28
- Forest Laboratories Inc. (Active Pharmaceutical Ingredient Watch).(financial data)(Brief Article)
- FOREST LABORATORIES Inc. posted fiscal second quarter 2003 net income up 79 percent to $143 million, or 77 ... FOREST LABORATORIES Inc. posted fiscal second quarter 2003 net income up 79 percent to $143 million, or 77 cents per share, 3 cents ahead of...
- Research articles 2002-10-21
- Business briefs
- Drugmakers trying to cut medication errors linked to pain pill -- Celebrex, the hot-selling new arthritis pill, sounds a lot like Celexa, a depression treatment, and Cerebyx, an anti-seizure drug. And it isn't just patients who are confused. Since Celebrex was launched in January, federal regulators have received...
- Research articles 1999-08-26
- Alzheimer's drug fails
- Forest Laboratories Inc., maker of the antidepressant Celexa, said its experimental medicine memantine failed in a study of patients with mild to moderate Alzheimer's disease. Shares of the New York- based drugmaker fell 12 percent, the biggest drop in almost three years. The findings will hurt Forest's bid to expand...
- Research articles 2003-06-20
- The Lawrence Summers Memorial Award. *.(The Front)(Brief Article)
- THE SEPTEMBER 2003 LAWRENCE SUMMERS MEMORIAL AWARD * goes to Forest Pharmaceuticals, makers of the drug citalopram, brand name Celexa. A Forest Pharmaceuticals-sponsored study found that citalopram, an antidepressant in the class of drugs called selective serotonin reuptake inhibitors, reduces compulsive shopping tendencies in...
- Research articles 2003-09-01
- FDA's "Hit List" List of Drugs With Potential Safety Concerns Features the Usual Suspects
- The FDA published a list of drugs that have developed safety signals worth reviewing in its adverse event reporting system. The list doesn't mean the drugs are dangerous, just that routine monitoring has thrown up a list of candidates that should be studied to see if there's more danger there...
- Blog posts 2009-02-05
- Forest Labs' Lexapro Flap Over JAMA Article Will Likely Be Examined by the Feds
- An editor of the Journal of the American Medical Association called a university professor "a nobody and a nothing" after he pointed out, correctly, that a JAMA author had failed to disclose a financial relationship with Forest Labs in an article about Lexapro, according to the WSJ. ...
- Blog posts 2009-03-16
- Forest Lab's Hard Sell of Anti-Depressant Raises Questions
- Derek Lowe submits: Forest Labs FRX has done very, very well with Lexapro escitalopram over the years. They're a comparatively small company, and their collaboration with Lundbeck (HLUKY.PK) also a comparatively small company in the antidepressant field has been the biggest event in their history. Lexapro...
- External links 2009-09-02
- Hands Off Healthcare! Sales Are Up!
- The U.S. Healthcare system is the most successful industry in the entire world. Other industries worldwide view it as THE ROLE MODEL for how to build a strong and vibrant business. Under the circumstances, it is insane to even contemplate the idea of "reform." Here's a perfect...
- Blog posts 2009-09-03
- Expect Targacept to Move Higher
- Dan Rosenblum submits: Having seen small biotech stocks Dov Pharma and Interneuron to name two that showed promising Phase 2 results in treatments for depression which ended up failing after the drugs advanced into Phase 3, I was somewhat skeptical of Targacept's TRGT rapid rise from $4...
- External links 2009-10-21
- << Previous
- page 1 of 1
- Next >>
